How did RGNX's Q4 earnings surprise impact investor sentiment?

Regenxbio Inc.'s (RGNX) Q4 earnings surprise had a negative impact on investor sentiment, as evidenced by the following points:

1. **Revenue and EPS Misses**: Regenxbio's Q4 earnings report revealed a revenue surprise and EPS surprise, with the company reporting a quarterly adjusted loss of $1.01 per share, higher than the same quarter last year. This indicated a continued financial struggle for the company, which likely contributed to a negative sentiment among investors.
2. **Analyst Ratings and Price Target Adjustments**: Despite the challenges, analysts from Raymond James and Stifel maintained positive ratings on Regenxbio, with Raymond James even resuming coverage with an "Outperform" rating. However, the sentiment may have been tempered by the recent news of a Sarepta patient's death from acute liver failure, which opened up a door for Regenxbio over its risk/benefit profile. This suggests that while there is some optimism, the negative earnings surprise could have dampened investor enthusiasm in the near term.
3. **Stock Price Reaction**: Following the earnings release, Regenxbio's stock price closed at $9.43, representing a -19.26% decline over the last three months. This significant drop reflects investor disappointment and potential withdrawal from the stock due to the perceived risks and uncertainties surrounding the company's financial performance and future prospects.

In conclusion, Regenxbio's Q4 earnings surprise, which included a revenue and EPS miss, has likely led to a negative sentiment among investors, despite some positive analyst ratings and price target adjustments. The stock price reaction to the earnings report further supports the notion that investor sentiment has been impacted negatively.